However, trust gaps among clinicians and patients are threatening to slow the adoption and impact of AI. Among HCPs, ...

Join the 4th Process Development for Cell Therapies Summit to hear from 24+ industry leaders from biopharma and service ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

France's Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in ...

AbbVie has claimed its first regulatory approval, from the FDA, for its C-met-targeting antibody-drug conjugate (ADC) Emrelis ...

MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare form of solid ...

US Health and Human Services (HHS) Secretary Robert F Kennedy Jr has made his first testimonies in front of Congress since he ...

Since December 2022, and COP decision 15/9, members of the Convention on Biological Diversity (the CBD) have been negotiating ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...